# Carsten Denkert

Source: https://onco.cc/people/carsten-denkert/  
OnCo record `carsten-denkert` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pathologist who established tumour-infiltrating lymphocytes as a biomarker in breast cancer.

## Summary

Carsten Denkert is Director of the Institute of Pathology at Philipps University Marburg and pathology lead for the German Breast Group (GBG). His specialisms are breast pathology, tumour-infiltrating lymphocytes and predictive biomarkers, using histopathology and immunohistochemistry. He is known for establishing tumour-infiltrating lymphocytes as a biomarker in breast cancer through analyses of GBG neoadjuvant trials, showing that stromal lymphocytes predict response to chemotherapy in triple-negative and HER2-positive disease. His Lancet Oncology paper pooled patients treated with neoadjuvant therapy to relate tumour-infiltrating lymphocytes to prognosis across breast cancer subtypes. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Institute of Pathology, Philipps University Marburg; GBG pathology lead
- Specialisms: Breast pathology; Tumour-infiltrating lymphocytes; Predictive biomarkers

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Denkert%20C%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20breast

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Histopathology & immunohistochemistry](https://onco.cc/technologies/histopathology-ihc/)
- companies: [German Breast Group (GBG)](https://onco.cc/companies/gbg/)
- terms: [Tumour-infiltrating lymphocytes (TILs)](https://onco.cc/terms/tils/)
- key papers: [Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials](https://onco.cc/key-papers/paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021/), [Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial](https://onco.cc/key-papers/paper-hahnen-geparsixto-germline-brca-jama-oncol-2017/), [KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer](https://onco.cc/key-papers/paper-keynote-522-nejm-2022/), [Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto](https://onco.cc/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/), [Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy](https://onco.cc/key-papers/paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018/)
- institutions: [University Cancer Center Frankfurt (UCT)](https://onco.cc/institutions/uct-frankfurt/)

---
JSON: https://onco.cc/api/v1/entities/carsten-denkert.json